Berlin, Germany

Frank Schwoebel

USPTO Granted Patents = 3 

Average Co-Inventor Count = 10.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Berlin, DE (2023)
  • Tuebingen, DE (2024)

Company Filing History:


Years Active: 2023-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Frank Schwoebel: Pioneering Innovations in Cancer Therapy

Introduction

Frank Schwoebel is an accomplished inventor based in Berlin, Germany, known for his significant contributions to the field of biotechnology. With three patents to his name, Schwoebel is dedicated to developing innovative solutions for cancer diagnosis and treatment.

Latest Patents

Schwoebel's latest inventions include groundbreaking antigen binding proteins that specifically target melanoma-associated antigens. His first patent involves antigen binding proteins directed against melanoma-associated antigen A (MAGE-A), which include engineered T cell receptors (TCRs) designed to bind to MAGE-A peptide/MHC complexes. These proteins hold great promise for the diagnosis, treatment, and prevention of cancers expressing MAGE-A.

In addition to his work on MAGE-A, Schwoebel has developed antigen binding proteins that specifically target the PRAME protein-derived antigens. This innovation provides a targeted approach to diagnosing and treating cancers that express the PRAME antigen. His inventions also encompass nucleic acids encoding the binding proteins, vectors, recombinant cells, and pharmaceutical compositions, showcasing a comprehensive approach to cancer therapy.

Career Highlights

Schwoebel works at Immatics Biotechnologies GmbH, where he utilizes his expertise to advance cutting-edge research and innovations in cancer therapeutics. His remarkable focus on antigen binding proteins reflects a commitment to harnessing the body’s immune response for more effective cancer treatments.

Collaborations

Throughout his career, Frank Schwoebel has collaborated with talented professionals, including Meike Hutt and Felix Unverdorben. This teamwork at Immatics Biotechnologies enables the synthesis of diverse skills in the pursuit of revolutionary cancer therapies, fostering an environment of innovation.

Conclusion

Frank Schwoebel stands out as a dedicated inventor whose work has the potential to transform the landscape of cancer treatment. By focusing on antigen binding proteins and collaborating with esteemed colleagues, he is paving the way for novel therapeutic approaches that may improve outcomes for patients facing cancer. With three patents and ongoing research, Schwoebel is an important figure in biotechnology and a source of inspiration for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…